Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jul 13;22(1):215–223. doi: 10.1093/annonc/mdq339

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — The cost-effectiveness plane (CEP) represents the results of 1000 simulations for incremental lifetime costs (the pharmacy retail price for trabectedin was assumed) and life years gained (LYG) for TRA → end-stage treatment (EST) versus EST (EST is fixed in the origin of the CEP). 95% confidence intervals for incremental costs and effects, and a dashed line showing where the threshold for €50 000 per LYG stands are shown in the CEP; all points under this line were associated with an incremental cost-effectiveness ratio of <€50 000 per LYG. This characterised 98.5% of the simulations.